Peptides Similar to CJC-1295 without DAC

Peptides Related to CJC-1295 without DAC#

CJC-1295 without DAC (Modified GRF 1-29) is one of several growth hormone secretagogues used in research settings. Understanding the differences between these compounds is essential for selecting the appropriate tool for specific research objectives. The most relevant comparisons are with CJC-1295 DAC (same peptide with albumin-binding modification), sermorelin (unmodified parent peptide), and ghrelin-mimetic peptides (complementary GH-releasing pathway).

CJC-1295 DAC#

The most important comparison is between the DAC and non-DAC forms of CJC-1295, as they share an identical peptide sequence but have dramatically different pharmacokinetic profiles. The DAC moiety enables covalent albumin binding, extending the half-life from approximately 30 minutes to 6 to 8 days.

This pharmacokinetic difference creates fundamentally different pharmacodynamic profiles. Modified GRF(1-29) produces discrete, time-limited GH pulses lasting 1 to 2 hours per injection, closely mimicking the natural pulsatile pattern of GH secretion. CJC-1295 DAC produces sustained GHRH receptor activation throughout the weekly dosing interval, resulting in continuous GH elevation with superimposed pulsatility.

The non-DAC form is preferred by researchers who want to study pulsatile GH stimulation, who value the ability to rapidly terminate pharmacological effects if needed, or who wish to more closely model physiological GH secretion. The DAC form is preferred for sustained GH axis stimulation, convenience (weekly vs multiple daily injections), and when consistent IGF-1 elevation is desired.

From a safety perspective, the non-DAC form has the significant advantage of rapid clearance. If adverse effects develop, the pharmacological action resolves within hours. With CJC-1295 DAC, adverse effects persist for days to weeks, and the albumin-conjugated peptide cannot be removed or antagonized.

Sermorelin (Native GRF 1-29)#

Sermorelin is the unmodified, natural 29-amino acid fragment of human GHRH. It was previously FDA-approved as Geref for diagnostic evaluation of GH deficiency and as Geref Diagnostic for stimulation testing, though both products have been discontinued.

The key structural difference is the absence of the four amino acid substitutions present in Modified GRF(1-29). This means sermorelin is susceptible to rapid DPP-IV cleavage, with a plasma half-life of less than 7 to 10 minutes compared to approximately 30 minutes for Modified GRF(1-29). Despite having identical receptor binding affinity, the shorter half-life means sermorelin produces a less robust GH pulse per injection.

Sermorelin's historical FDA approval provides a level of clinical validation that Modified GRF(1-29) lacks. However, Modified GRF(1-29) is considered pharmacologically superior due to its improved stability and more consistent GH-releasing activity per injection.

GHRP-6 and Other Ghrelin-Mimetics#

GHRP-6 (Growth Hormone Releasing Peptide 6) is a synthetic hexapeptide that stimulates GH release through the growth hormone secretagogue receptor (GHS-R1a), the endogenous receptor for ghrelin. This represents a distinct and complementary pathway to the GHRH pathway used by Modified GRF(1-29).

The key differences are in selectivity and side effect profile. GHRP-6 produces robust GH release but also stimulates appetite (through the ghrelin pathway), and can increase cortisol and prolactin levels at higher doses. Modified GRF(1-29) produces cleaner GH stimulation without significant effects on hunger, cortisol, or prolactin.

The combination of Modified GRF(1-29) with a ghrelin-mimetic (GHRP-6 or ipamorelin) produces synergistic GH release that exceeds the additive effect of either alone. Ipamorelin is generally preferred over GHRP-6 for combination use because of its greater selectivity (less cortisol and prolactin elevation) and lack of appetite-stimulating effects.

Summary Comparison#

Clinical Positioning#

CJC-1295 without DAC occupies a middle ground between sermorelin (less stable but FDA-validated) and CJC-1295 DAC (more convenient but less physiological and less reversible). Its primary research niche is in combination protocols with ghrelin-mimetic peptides, where the synergistic GH-releasing effect is the primary objective. For standalone GH axis stimulation, CJC-1295 DAC offers superior convenience with weekly dosing, while Modified GRF(1-29) offers a more physiological stimulation pattern.

Related Reading#

• CJC-1295 without DAC overview and research guide
• CJC-1295 without DAC research evidence
• CJC-1295 without DAC dosing protocols